Cidofovir for the treatment of recurrent respiratory papillomatosis: A review of the literature

Pharmacotherapy

Volumn 25, Issue 7, 2005, Pages 977-989

  Shehab, Nadine ^a,b   Sweet, Burgunda V ^a,b   Hogikyan, Norman D ^a,b,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cidofovir; Recurrent respiratory papillomatosis

Indexed keywords

ACICLOVIR; ALPHA2B INTERFERON; CIDOFOVIR;

ADENOCARCINOMA; CARBON DIOXIDE LASER; CARCINOGENICITY; CLINICAL FEATURE; CLINICAL TRIAL; DEBRIDEMENT; DISEASE COURSE; DOSE RESPONSE; DRUG INDICATION; DRUG SAFETY; EDEMA; FIBROSIS; HEADACHE; HISTOPATHOLOGY; HOARSENESS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; INFLAMMATORY DISEASE; LARYNX CARCINOMA; LARYNX PAPILLOMATOSIS; LONG TERM CARE; MALIGNANT TRANSFORMATION; MUSCLE DISEASE; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PAIN; PALLIATIVE THERAPY; PAPILLOMATOSIS; POSTOPERATIVE COMPLICATION; PRECORDIAL PAIN; RASH; RECURRENT INFECTION; RECURRENT RESPIRATORY PAPILLOMATOSIS; RELAPSE; REMISSION; REVIEW; RISK ASSESSMENT; SCAR; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS TRANSMISSION; VOICE;

ADULT; ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS; CYTOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; LARYNGEAL NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; PAPILLOMA; PHOSPHONIC ACIDS; RESPIRATORY TRACT NEOPLASMS;

EID: 21444450806     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.7.977     Document Type: Review

References (99)

1. Gomez MA, Drut R, Lojo MM, Drut RM. Detection of human papillomavirus in juvenile laryngeal papillomatosis using polymerase chain reaction. Medicina 1995;55:213-17.
2. 2 laser plume from recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1991;104:191-5.
3. Bonnez W, Reichman RC. Papillomaviruses. In: Mandell GL, Bennett JE, Dolin K, eds. Principles and practice of infectious disease. Philadelphia, PA: Churchill Livingstone, 2000:1630-44.
4. Phelps WC, Alexander KA. Antiviral therapy for human papillomaviruses: rationale and prospects. Ann Intern Med 1995;123;368-82.
5. Hill DS, Akhtar S, Corroll A, Croft CB. Quality of life issues in recurrent respiratory papillomatosis. Clin Otolaryngol 2000;25:153-60.
6. Bishai D, Kashima H, Shah K. The cost of juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2000;126:935-9.
7. Reeves WC, Ruparelia SS, Swanson KI, Derkay CS, Marcus A, Unger ER. National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003;129:976-82.
8. Doyle DJ, Gianoli GJ, Espinola T, Miller RH. Recurrent respiratory papillomatosis: juvenile versus adult forms. Laryngoscope 1994;104(5 pt 1):523-7.
9. Morgan AH, Zitsch RP. Recurrent respiratory papillomatosis in children: a retrospective study of management and complications. Ear Nose Throat J 1986;65:19-28.
10. Derkay CS. Task force on recurrent respiratory papillomas: a preliminary report. Arch Otolaryngol Head Neck Surg 1995;121:1386-91.
11. Derkay CS. Recurrent respiratory papillomatosis. Laryngoscope 2001;111:57-69.
12. Puranen M, Yliskoski M, Saarikoski S, Syrjanen K, Syrjanen S. Vertical transmission of human papillomavirus from infected mothers to their newborn babies and persistence of the virus in childhood. Am J Obstet Gynecol 1996;174:694-9.
13. Smith EM, Johnson SR, Cripe TP, Pignatari S, Turek L. Perinatal vertical transmission of human papillomavirus and subsequent development of respiratory tract papillomatosis. Ann Otol Rhinol Laryngol 1991;100:479-83.
14. Tseng CJ, Liang CC, Soong YK, Pao CC. Perinatal transmission of human papillomavirus in infants: relationship between infection rate and mode of delivery. Obstet Gynecol 1998;91:92-6.
15. Shah KV, Stern WF, Shah FK, Bishai D, Kashima HK. Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatr Infect Dis J 1998;17:372-6.
16. Kashima HK, Shah F, Lyles A, et al. A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope 1992;102:9-13.
17. Shah K, Kashima H, Polk BF, Shah F, Abbey H, Abramson A. Rarity of cesarean delivery in cases of juvenile-onset respiratory papillomatosis. Obstet Gynecol 1986;68:795-9.
18. Sedlacek T, Lindheim S, Eder C, et al. Mechanism of human papillomavirus transmission at birth. Am J Obstet Gynecol 1989;161:55-9.
19. Tseng CJ, Lin CY, Wang RL, et al. Possible transplacental transmission of human papillomavirus. Am J Obstet Gynecol 1992;166(1 pt 1):35-40.
20. Clarke J, Terry RM, Lacey CJ. A study to estimate the prevalence of upper respiratory tract papillomatosis in patients with genital warts. Int J STD AIDS 1991;2:144-5.
21. Kramer SS, Wehunt WD, Stocker JT, Kashima H. Pulmonary manifestations of juvenile laryngotracheal papillomatosis. Am J Roentgenol 1985;144:687-94.
22. Blackledge F, Anand VK. Tracheobronchial extension of recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2000;109:812-18.
23. Steinberg BM, Topp WC, Schneider PS, Abramson AL. Laryngeal papillomavirus infection during clinical remission. N Engl J Med 1983;308:1261-4.
24. Ferenczy A, Mitao M, Nagai N, Silverstein SJ, Crum CP. Latent papillomavirus and recurring genital warts. N Engl J Med 1985;313:784-8.
25. Kimberlin DW. Pharmacotherapy of recurrent respiratory papillomatosis. Expert Opin Pharmacother 2002;3:1091-9.
26. Cook JR, Hill DA, Humphrey PA, Pfeifer JP, El-Mofty SK. Squamous cell carcinoma arising in recurrent respiratory papillomatosis with pulmonary involvement: emerging common pattern of clinical features and human papillomavirus serotype association. Mod Pathol 2000;13:914-18.
27. Rady PL, Schnadig VJ, Weiss RL, Hughes TK, Tyring SK. Malignant transformation of recurrent respiratory papillomatosis associated with integrated human papillomavirus type 11 DNA and mutation of p53. Laryngoscope 1998;108:735-40.
28. Orphanidou D, Dimakou K, Latsi P, et al. Recurrent respiratory papillomatosis with malignant transformation in a young adult. Respir Med 1996;90:53-5.
29. Doyle DJ, Henderson LA, Lejeune FE Jr, Miller RH. Changes in human papillomavirus typing of recurrent respiratory papillomatosis progressing to malignant neoplasm. Arch Otolaryngol Head Neck Surg 1994;120:1273-6.
30. Gaylis B, Hayden RE. Recurrent respiratory papillomatosis: progression to invasion and malignancy. Am J Otolaryngol 1991;12:104-12.
31. Schnadig VJ, Clark WD, Clegg TJ, Yao CS. Invasive papillomatosis and squamous carcinoma complicating juvenile laryngeal papillomatosis. Arch Otolaryngol Head Neck Surg 1986;112:966-71.
32. Sakakura A, Yamamoto Y, Takasaki T, Makimoto K, Nakamura M, Takahashi H. Recurrent laryngeal papillomatosis developing into laryngeal carcinoma with human papilloma virus (HPV) type 18: a case report. J Laryngol Otol 1996;110:75-7.
33. Guillou L, Sahli R, Chaubert P, Monnier P, Cuttat JF, Costa J. Squamous cell carcinoma of the lung in a nonsmoking, nonirradiated patient with juvenile laryngotracheal papillomatosis: evidence of human papillomavirus-11 DNA in both carcinoma and papillomas. Am J Surg Pathol 1991;15:891-8.
34. Helmuth RA, Strate RW. Squamous carcinoma of the lung in a nonirradiated, nonsmoking patient with juvenile laryngotracheal papillomatosis. Am J Surg Pathol 1987;11:643-50.
35. Patel N, Rowe M, Tunkel D. Treatment of recurrent respiratory papillomatosis in children with the microdebrider. Ann Otol Rhinol Laryngol 2003;112:7-10.
36. 2 laser removal of recurrent respiratory papillomas: a prospective analysis. Laryngoscope 2003;113:139-43.
37. Perkins JA, Inglis AF Jr, Richardson MA. latrogenic airway stenosis with recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 1998;124:281-7.
38. Ossoff RH, Werkhaven JA, Dere H. Soft-tissue complications of laser surgery for recurrent respiratory papillomatosis. Laryngoscope 1991;101:1162-6.
39. Crockett DM, McCabe BF, Shive CJ. Complications of laser surgery for recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 1987;96:639-44.
40. Wetmore SJ, Key JM, Suen JY. Complications of laser surgery for laryngeal papillomatosis. Laryngoscope 1985;95:798-801.
41. Harries ML, Juman S, Bailey CM. Recurrent respiratory papillomatosis in the larynx: re-emergence of clinical disease following surgery. Int J Pediatr Otorhinolaryngol 1995;31:259-62.
42. Shapiro AM, Rimell FL, Shoemaker D, Pou A, Stool SE. Tracheotomy in children with juvenile-onset recurrent respiratory papillomatosis: the Children's Hospital of Pittsburgh experience. Ann Otol Rhinol Laryngol 1996;105:1-5.
43. Lopez Aguado D, Perez Pinero B, Betancor L, Mendez A, Campos Banales E. Acyclovir in the treatment of laryngeal papillomatosis. Int J Pediatr Otorhinolaryngol 1991;21:269-74.
44. Endres DR, Bauman NM, Burke D, Smith RJ. Acyclovir in the treatment of recurrent respiratory papillomatosis: a pilot study. Ann Otol Rhinol Laryngol 1994;103(4 pt 1):301-5.
45. Kiroglu M, Cetik F, Soylu L, et al. Acyclovir in the treatment of recurrent respiratory papillomatosis: a preliminary report. Am J Otolaryngol 1994;15:212-14.
46. Morrison GA, Kotecha B, Evans JN. Ribavirin treatment for juvenile respiratory papillomatosis. J Laryngol Otol 1993;107:423-6.
47. Mutz I, Zoubek A, Baumgartner F. Successful bleomycin treatment of bronchopulmonary papillomatosis in a child [in German]. Monatsschr Kinderheilkd 1983;131:464-6.
48. Winnen P. Intrafocal bleomycin injection in florid oral papillomatosis (papillomatosis mucosae carcinoides) [in German]. Z. Hautkr 1983;58:733-41.
49. Mehta P, Herold N. Regression of juvenile laryngobronchial papillomatosis with systemic bleomycin therapy. J Pediatr 1980;97:479-80.
50. Harcourt JP, Worley G, Leighton SE. Cimetidine treatment for recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 1999;51:109-13.
51. Leventhal BG, Kashima HK, Mounts P, et al. Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-N1: papilloma study group. N Engl J Med 1991;325:613-17.
52. Healy GB, Gelber RD, Trowbridge AL, Grundfast KM, Ruben RJ, Price KN. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon: results of a multicenter randomized controlled clinical trial. N Engl J Med 1988;319:407-13.
53. Leventhal BG, Kashima HK, Week PW, et al. Randomized surgical adjuvant trial of interferon alfa-n1 in recurrent papillomatosis. Arch Otolaryngol Head Neck Surg 1988;114:1163-9.
54. Schuurman AM, van den Broek P. Results of treatment with α-interferon in adult-onset laryngeal papillomatosis. Clin Otolaryngol 1986;11:447-53.
55. McCabe B, Clark KF. Interferon and laryngeal papillomatosis: the Iowa experience. Ann Otol Rhinol Laryngol 1983;92(1 pt 1):2-7.
56. Haglund S, Lundquist PG, Cantell K, Strander H. Interferon therapy in juvenile laryngeal papillomatosis. Arch Otolaryngol 1981;107:327-32.
57. Lippman SM, Donovan DT, Frankenthaler RA, et al. 13-cis-retinoic acid plus interferon-α 2a in recurrent respiratory papillomatosis. J Natl Cancer Inst 1994;86:859-61.
58. Rosen CA, Woodson GE, Thompson JW, Hengesteg AP, Bradlow HL. Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1998;118:810-15.
59. Coll DA, Rosen CA, Auborn K, Potsic WP, Bradlow HL. Treatment of recurrent respiratory papillomatosis with indole-3-carbinol. Am J Otolaryngol 1997;18:283-5.
60. Avidano MA, Singleton GT. Adjuvant drug strategies in the treatment of recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1995;112:197-202.
61. van der Beek JM, Cremers CW, van den Broek P. Successful methotrexate therapy in oral florid papillomatosis. Clin Otolaryngol 1980;5:365-71.
62. Shikowitz MJ, Abramson AL, Freeman K, Steinberg BM, Nouri M. Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope 1998;108:962-7.
63. Abramson AL, Shikowitz MJ, Mullooly VM, Steinberg BM, Hyman RB. Variable light-dose effect on photodynamic therapy for laryngeal papillomas. Arch Otolaryngol Head Neck Surg 1994;120:852-5.
64. Bujia J, Feyh J, Kastenbauer E. Photodynamic therapy with derivatives from hematoporphyrines for recurrent laryngeal papillomatosis of the children. Early results [in Spanish]. An Otorrinolaringol Ibero Am 1993;20:251-9.
65. Osborne C, LeBoeuf H, Jones DV Jr. Isotretinoin in respiratory papillomatosis [letter]. Ann Intern Med 2000;132:1007.
66. Eicher SA, Taylor-Cooley LD, Donovan DT. Isotretinoin therapy for recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 1994;120:405-9.
67. Bell R, Hong WK, Itri LM, McDonald G, Strong MS. The use of cis-retinoic acid in recurrent respiratory papillomatosis of the larynx: a randomized pilot study. Am J Otolaryngol 1988;9:161-4.
68. De Clercq E. Antivirals for the treatment of herpes virus infections. J Antimicrob Chemother 1993;32(suppl A):121-32.
69. Ho HT, Woods KL, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJ. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2- (phosphonylmethoxy)propyl]cytosine. Mol Pharmacol 1992;41:197-202.
70. De Clercq E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol Sci 2002;23:456-8.
71. Johnson JA, Gangemi JD. Selective inhibition of human papillomavirus-induced cell proliferation by (s)-1-[3-hydroxy-2- (phophonylmethoxy)propyl]cytosine. Antimicrob Agents Chemother 1999;43:1198-205.
72. Andrei G, Snoeck R, Schols D, De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res 2001;12:397-408.
73. Abdulkarim B, Sabri S, Zelenika D, et al. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies. Oncogene 2003;22:2260-71.
74. Abdulkarim B, Sabri S, Deutsch E, et al. Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 2002;21:2334-46.
75. Van Custem E, Snoeck R, Van Ranst M, et al. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (s)-1-(3-hydroxy-2-phosphonylmethoxypropy)cytosine. J Med Virol 1995;45: 230-5.
76. Gilead Sciences, Inc. Vistide (cidofovir) package insert. Foster City, CA; 2000.
77. Pransky SM, Magit AE, Kearns DB, Rang DR, Duncan NO. Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg 1999;125:1143-8.
78. Pransky SM, Brewster DF, Magit AE, Kearns DB. Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2000;126:1239-43.
79. Pransky SM, Albright JT, Magit AE. Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir. Laryngoscope 2003;113:1583-7.
80. El Hakim H, Waddell AN, Crysdale WS. Observations on the early results of treatment of recurrent respiratory papillomatosis using cidofovir. J Otolaryngol 2002;31:333-5.
81. Chhetri DK, Shapiro NL. A scheduled protocol for the treatment of juvenile recurrent respiratory papillomatosis with intralesional cidofovir. Arch Otolaryngol Head Neck Surg 2003;129:1081-5.
82. Milczuk HA. Intralesional cidofovir for the treatment of severe juvenile recurrent respiratory papillomatosis: long-term results in 4 children. Otolaryngol Head Neck Surg 2003;128:788-94.
83. Akst LM, Lee W, Discolo C, Knott D, Younes A, Koltai PJ. Stepped-dose protocol of cidofovir therapy in recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg 2003;129:841-6.
84. Snoeck R, Wellens W, Desloovere C, et al. Treatment of severe laryngeal papillomatosis with intralesional injection of cidofovir [(s)-1-(3-hydroxy-2- phosphonylmethoxypropyl) cytosine]. J Med Virol 1998;54:219-25.
85. Bielamowicz S, Villagomez V, Stager SV, Wilson WR. Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort. Laryngoscope 2002;112:696-9.
86. Naiman AN, Ceruse P, Coulombeau B, Froehlich P. Intralesional cidofovir and surgical excision for laryngeal papillomatosis. Laryngoscope 2003;113:2174-81.
87. Neumann K, Pudszuhn A, Welzel C, Bartel-Friedrich S, Passmann M. Intralesional cidofovir injections for recurrent laryngeal papillomatosis: first results [in German]. Laryngorhinootologie 2003;82:700-6.
88. Chhetri DK, Blumin JH, Shapiro NL, Berke GS. Office-based treatment of laryngeal papillomatosis with percutaneous injection of cidofovir. Otolaryngol Head Neck Surg 2002;126:642-8.
89. Derkay CS, Malis DJ, Zalzal G, Wiatrak BJ, Kashima HK, Coltrera MD. A staging system for assessing severity of disease and response to therapy in recurrent respiratory papillomatosis. Laryngoscope 1998;108:935-7.
90. Dancey DR, Chamberlain DW, Krajden M, Palefsky J, Albert PW, Downey GP. Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir: case report and review of the literature. Chest 2000;118: 1210-14.
91. Armbruster C, Kreuzer A, Vorbach H, Huber M, Armbruster C. Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon alpha-2b. Eur Respir J 2001;17:830-1.
92. Van Valckenborgh I, Wellens W, De Boeck K, Snoeck R, De Clercq E, Feenstra L. Systemic cidofovir in papillomatosis [online exclusive article]. Clin Infect Dis 2001;32:e62-4. Available from www.journals.uchicago.edu/CID/ journal/issues/ v32n3/000253/000253.html. Accessed August 31, 2004.
93. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999;36:127-43.
94. Chhetri DK, Jahan-Parwar B, Hart SD, Bhuta SM, Berke GS, Shapiro NL. Local and systemic effects of intralaryngeal injection of cidofovir in a canine model. Laryngoscope 2003;113:1922-6.
95. Center for Drug Evaluation and Research. Minutes from the joint antiviral drugs committee and ophthalmic drugs subcommittee, 1996 Mar 14-15. Available from http://www.fda. gov/cder/foi/adcomm/96/avdac_joint_031496_summmin_ac.pd f. Accessed August 31, 2004.
96. Afouna MI, Mehta SC, Ghanem AH, et al. Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV-1 infection in hairless mice. J Pharm Sci 1999;88:530-4.
97. Aduma P, Connelly CM, Srinivas RV, Fridland A. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Mol Pharmacol 1995;47:816-22.
98. Johnson JA, Gangemi JD. α-Interferon augments cidofovir's antiviral and antiproliferative activities. Antimicrob Agents Chemother 2003;47:2022-6.
99. Rabah R, Lancaster WD, Thomas R, Gregoire L. Human papillomavirus-11- associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediatr Dev Pathol 2001;4:68-72.